A medically relevant capsular polysaccharide in Acinetobacter baumannii is a potential vaccine candidate. Issue 10 (7th March 2017)

• Record Type: Journal Article
• Authors: Yang, Feng-Ling; Lou, Tze-Chi; Kuo, Shu-Chen; Wu, Wan-Ling; Chern, Jeffy; Lee, Yi-Tzu; Chen, Shui-Tsung; Zou, Wei; Lin, Nien-Tsung; Wu, Shih-Hsiung
• Is Part Of: Vaccine. Volume 35:Issue 10(2017)
• Page Start: 1440
• Page End: 1447
• Publication Date: 2017-03-07
• Subjects: Acinetobacter baumannii -- Capsular polysaccharide -- Passive immunity -- Clinic population distribution; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2017.01.060
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Concerns of Acinetobacter baumannii infection have increased due to the emergence of multi-drug resistance. In the present study, we determined the capsular polysaccharide (CPS) structure of A. baumannii SK44, a clinical isolate from Taiwan, to consist of pentasaccharide repeats. We found that CPS-induced antibody provided 55% protection against challenge in an animal model. The CPS-specific antibody reacted with the surface components of about 62% clinical isolates (342/554 strains) from cross-sectional and longitudinal studies by dot-immunoassay. Pulsed-field gel electrophoresis of positive strains showed the antibody covered different clonalites of A. baumannii clinical isolates. Meanwhile, using the CPS antibody as a probe, we found a number of outer membrane proteins bound to the antibody, including OmpA/motB, TonB-dependent receptor, and Omp38, indicating their association with CPS. These results might lead to the use of the capsular polysaccharide as a vaccine to prevent A. baumannii infection.